RxDoctor Payments Data

Eduardo Maraboto

Adult Health · Austin, TXNPI 1174871339

Payments from drug & device makers

$4,218in general payments, 2019–2025

Across 109 payments — averaging $38.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$662
  • Neurocrine Biosciences, Inc.$395
  • Johnson & Johnson$382
  • Lundbeck LLC$345
  • Teva Pharmaceuticals USA, Inc.$286
  • Axsome Therapeutics, Inc.$277
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,218 in reported general payments places this provider in the 85th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$102,651
Medicare patients
189
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide44$22,061
VraylarCariprazine Hcl11$15,548
FetzimaLevomilnacipran Hcl18$9,224
BelsomraSuvorexant14$5,904
Duloxetine Hcl153$3,517
Desvenlafaxine Succinate ErDesvenlafaxine Succinate54$2,964
Vilazodone Hcl21$2,329
Sertraline Hcl238$2,141
Quetiapine Fumarate127$2,119
Gabapentin187$1,863
Memantine Hcl ErMemantine Hcl32$1,647
Divalproex Sodium ErDivalproex Sodium25$1,627
Mirtazapine95$1,568
Venlafaxine Hcl ErVenlafaxine Hcl86$1,515
Bupropion XlBupropion Hcl103$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$662$24,77229 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$36$22,06144 claims
Almatica Pharma LLCSertraline Hcl$22$2,141238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 933 adult health providers in Texas.

Other adult health in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →